Chloe Markey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chloe Markey has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Reker
Duke University
4 shared publications - Hannah Lee
Duke University
3 shared publications - Zachary Fralish
Duke University
3 shared publications - Alexander A. Mestre
Department of Biochemistry, Duke University School of Medicine, Durham, NC, 27710, USA
1 shared publication - Beth Anderson
University of Notre Dame
1 shared publication - Brittany S. Morgan
Department of Chemistry, Duke University, Durham, NC, 27708-0346, USA
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
PCAN-PIE: A Machine Learning Tool for Prioritizing Prodrug Candidates by Predicted Bioactivation
Prodrug design enhances critical drug properties by creating drug derivatives with improved properties while harnessing metabolic activation to regenerate the active pharmaceutical ingredient (API) in vivo . However, reliably predicting whether a prodrug converts to the intended API remains challenging, causing project failures and limiting systematic exploration of prodrug design spaces. Here, we developed PCAN-PIE (Prodrug CAndidate Navigator using a Paired-Input Ensemble), a machine learning tool to de-risk prodrug design by distinguishing prodrug candidates likely to release their intended API from those unlikely to activate. PCAN-PIE demonstrates strong performance across different approved prodrug activation chemistries, can identify competing metabolic pathways that may compromise activation, and correctly triages chemically plausible but unreported transformation products. Attribution analysis suggests that PCAN-PIE bases its predictions on chemically meaningful reactive substructures, providing medicinal chemists with an interpretable rationale for candidate prioritization. In a prospective four-candidate prodrug design campaign, PCAN-PIE successfully prioritized the two candidates that ultimately demonstrated measurable API formation and cellular activity, while deprioritizing two candidates that showed negligible conversion and activity. Taken together, this work establishes PCAN-PIE as a focused computational tool for prioritizing prodrug candidates and provides a framework for integrating structure-based prediction into rational prodrug design to support the development of safer and more effective medicines.
- 25 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPCAN-PIE: A Machine Learning Tool for Prioritizing Prodrug Candidates by Predicted Bioactivation
Prodrug design enhances critical drug properties by creating drug derivatives with improved properties while harnessing metabolic activation to regenerate the active pharmaceutical ingredient (API) in vivo . However, reliably predicting whether a prodrug converts to the intended API remains challenging, causing project failures and limiting systematic exploration of prodrug design spaces. Here, we developed PCAN-PIE (Prodrug CAndidate Navigator using a Paired-Input Ensemble), a machine learning tool to de-risk prodrug design by distinguishing prodrug candidates likely to release their intended API from those unlikely to activate. PCAN-PIE demonstrates strong performance across different approved prodrug activation chemistries, can identify competing metabolic pathways that may compromise activation, and correctly triages chemically plausible but unreported transformation products. Attribution analysis suggests that PCAN-PIE bases its predictions on chemically meaningful reactive substructures, providing medicinal chemists with an interpretable rationale for candidate prioritization. In a prospective four-candidate prodrug design campaign, PCAN-PIE successfully prioritized the two candidates that ultimately demonstrated measurable API formation and cellular activity, while deprioritizing two candidates that showed negligible conversion and activity. Taken together, this work establishes PCAN-PIE as a focused computational tool for prioritizing prodrug candidates and provides a framework for integrating structure-based prediction into rational prodrug design to support the development of safer and more effective medicines.
- Open Access
- 3 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Ensemble Siamese Neural Networks for Prodrug Activation Prediction
Prodrug design enhances critical drug properties by harnessing metabolic activation to release the active pharmaceutical ingredient. However, predicting prodrug activation remains challenging, causing design failures and limiting systematic exploration of prodrug design spaces. Here, we developed an ensemble Siamese neural network model to predict prodrug activation. We demonstrate that our model accurately captures prodrug activations from molecular structure, including in a prospective, in-house prodrug development effort. The model reliably identifies competing metabolic pathways and distinguishes true activations from metabolic counterfactuals. Attribution analysis reveals that predictions are driven by chemically meaningful substructures associated with site-specific reactivity. Taken together, this work establishes a generalizable framework for prodrug activation prediction and suggests that key determinants of metabolic reactivity can be learned directly from molecular structure, which could enable more rational prodrug design to accelerate the development of safer and more effective medicines.
- 3 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEnsemble Siamese Neural Networks for Prodrug Activation Prediction
Prodrug design enhances critical drug properties by harnessing metabolic activation to release the active pharmaceutical ingredient. However, predicting prodrug activation remains challenging, causing design failures and limiting systematic exploration of prodrug design spaces. Here, we developed an ensemble Siamese neural network model to predict prodrug activation. We demonstrate that our model accurately captures prodrug activations from molecular structure, including in a prospective, in-house prodrug development effort. The model reliably identifies competing metabolic pathways and distinguishes true activations from metabolic counterfactuals. Attribution analysis reveals that predictions are driven by chemically meaningful substructures associated with site-specific reactivity. Taken together, this work establishes a generalizable framework for prodrug activation prediction and suggests that key determinants of metabolic reactivity can be learned directly from molecular structure, which could enable more rational prodrug design to accelerate the development of safer and more effective medicines.
- Open Access
Identification of 4,5,6,7-Tetrabromo-1 H -benzotriazole (TBB) as a Small Molecule MESH1 Inhibitor that Suppresses Ferroptosis
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com
Open AccessIdentification of 4,5,6,7-Tetrabromo-1 H -benzotriazole (TBB) as a Small Molecule MESH1 Inhibitor that Suppresses Ferroptosis
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com
- Open Access
- 7 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Defined by Shape: Elucidating the Molecular Recognition of Dynamic Loops with Covalent Ligands
Protein loops harness conformational heterogeneity to perform an array of functions, ranging from catalyzing enzymatic reactions to communicating allosteric signals. Although attractive targets for small molecule modulation, these functional hubs are often considered unligandable due to their lack of well-defined binding pockets and highly dynamic structure. Recent studies, however, have demonstrated the power of covalent chemistry to selectively capture cryptic pockets formed by protein loops. Herein, we leverage machine learning to elucidate the molecular basis of covalent ligand:loop recognition in the transcriptional coactivator Med25. Key to our success was classification by ligand shape prior to model training, which led to descriptive and predictive models. The models were experimentally validated through the synthesis and in vitro testing of novel top-ranked ligands, revealing canonical structure-affinity relationships, including an activity cliff. Further feature analyses identified traditional topological and spatial parameters predictive of binding, and molecular modeling uncovered a potential binding pocket with at least two distinct conformations with high shape complementarity. Collectively, these findings reveal the hidden potential of dynamic loops as specific sites for covalent small molecule modulation, challenging the notion that protein loops are unligandable and demonstrating their capacity for exquisite, shape-based molecular recognition.
- 7 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDefined by Shape: Elucidating the Molecular Recognition of Dynamic Loops with Covalent Ligands
Protein loops harness conformational heterogeneity to perform an array of functions, ranging from catalyzing enzymatic reactions to communicating allosteric signals. Although attractive targets for small molecule modulation, these functional hubs are often considered unligandable due to their lack of well-defined binding pockets and highly dynamic structure. Recent studies, however, have demonstrated the power of covalent chemistry to selectively capture cryptic pockets formed by protein loops. Herein, we leverage machine learning to elucidate the molecular basis of covalent ligand:loop recognition in the transcriptional coactivator Med25. Key to our success was classification by ligand shape prior to model training, which led to descriptive and predictive models. The models were experimentally validated through the synthesis and in vitro testing of novel top-ranked ligands, revealing canonical structure-affinity relationships, including an activity cliff. Further feature analyses identified traditional topological and spatial parameters predictive of binding, and molecular modeling uncovered a potential binding pocket with at least two distinct conformations with high shape complementarity. Collectively, these findings reveal the hidden potential of dynamic loops as specific sites for covalent small molecule modulation, challenging the notion that protein loops are unligandable and demonstrating their capacity for exquisite, shape-based molecular recognition.
- Open Access
- 27 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Ensemble Siamese Neural Networks for Prodrug Activation Prediction
Prodrug design enhances critical drug properties without affecting potency by harnessing metabolic activation to release the active pharmaceutical ingredient (API). However, predicting prodrug activation remains challenging, causing design failures and limiting systematic exploration of the prodrug design space. Here, we developed an ensemble Siamese neural network model to predict prodrug activation. We demonstrate that our model accurately predicts 95% of all approved prodrugs, compared to less than 75% for any of the currently established metabolism models. Prospective validation on in-house designed prodrugs further confirmed the model’s ability to rank prodrug candidates by their observed release profiles. This work establishes a generalizable framework for prodrug activation prediction and provides a foundation for rational prodrug design, with the potential to accelerate the development of safer and more effective medicines.
- 27 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEnsemble Siamese Neural Networks for Prodrug Activation Prediction
Prodrug design enhances critical drug properties without affecting potency by harnessing metabolic activation to release the active pharmaceutical ingredient (API). However, predicting prodrug activation remains challenging, causing design failures and limiting systematic exploration of the prodrug design space. Here, we developed an ensemble Siamese neural network model to predict prodrug activation. We demonstrate that our model accurately predicts 95% of all approved prodrugs, compared to less than 75% for any of the currently established metabolism models. Prospective validation on in-house designed prodrugs further confirmed the model’s ability to rank prodrug candidates by their observed release profiles. This work establishes a generalizable framework for prodrug activation prediction and provides a foundation for rational prodrug design, with the potential to accelerate the development of safer and more effective medicines.